Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
PDF) Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials | Haematologica
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design | Future Oncology
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multiple Myeloma | PPT
Elotuzumab Plus Pomalidomide and Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma - Hematology Advisor
Drug receives priority review for second MM indication | MDedge Hematology and Oncology
Elotuzumab (Empliciti) Drug Info
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Combination Therapies - POMALYST® (pomalidomide)
Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma - YouTube
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
NEJM on X: "New research into elotuzumab plus pomalidomide and dexamethasone for #MultipleMyeloma explained in Quick Take video: https://t.co/Aa2Q1U86zg https://t.co/YJK9tdF7wE" / X
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
